검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 3개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor HbA1c ↓2.4%·t½ 6 h | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor Weight ↓14.9%·t½ ~1 week (SC) | |
|---|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) | Dupixent (dupilumab) |
Overview Company | Eli Lilly | Novo Nordisk | Sanofi / Regeneron |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor | IL-4Rα |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Atopic dermatitis, asthma, CRSwNP, EoE |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
MoA Mechanism | Dual GIP/GLP-1R agonism → enhanced insulin secretion, weight loss, lipolysis | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety | targeting specific inflammatory pathway |
MoA Biomarker | HbA1c, body weight, triglycerides | HbA1c, body weight, waist circumference | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu |
PK/PD Half-life | 6 h | ~1 week (SC) | — |
PK/PD Species | Mouse | Mouse, HbA1c, fasting glucose, weight | — |
PK/PD Animal (cat.) | Mouse | Mouse | In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | PD |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat | Mouse |
Toxicology Animal (cat.) | Mouse, Rat | NHP | Mouse |
Toxicology Major finding | — | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | — |
Toxicology CRS | — | N/A | — |
Clinical Primary efficacy | HbA1c ↓2.4% | Weight ↓14.9% | ORR 0.45% |
Clinical ORR | HbA1c ↓2.4% (SURPASS-2 vs semaglutide 1 mg) | Weight ↓14.9% vs placebo (STEP 1) | -0.45 |
Clinical PFS | Weight ↓20% at 72 wk (SURMOUNT-1) | MACE benefit in SELECT (obesity + CVD) | — |
Clinical Result source | SURPASS-2 / SURMOUNT-1 | STEP 1 / SELECT | ClinicalTrials.gov NCT02912468 |
Clinical Data Tier / Score | S · 77 | B · 75 | C · 65 |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Dose / schedule | — | q1w SC (titrated) or oral daily | — |
Clinical Clinical sync | 2026년 7월 20일 (7일 전) | 2026년 7월 20일 (7일 전) | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 3개 · 차세대 보드에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor HbA1c ↓2.4%·t½ 6 h | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor Weight ↓14.9%·t½ ~1 week (SC) | |
|---|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) | Dupixent (dupilumab) |
Overview Company | Eli Lilly | Novo Nordisk | Sanofi / Regeneron |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor | IL-4Rα |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Atopic dermatitis, asthma, CRSwNP, EoE |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
MoA Mechanism | Dual GIP/GLP-1R agonism → enhanced insulin secretion, weight loss, lipolysis | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety | targeting specific inflammatory pathway |
MoA Biomarker | HbA1c, body weight, triglycerides | HbA1c, body weight, waist circumference | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu |
PK/PD Half-life | 6 h | ~1 week (SC) | — |
PK/PD Species | Mouse | Mouse, HbA1c, fasting glucose, weight | — |
PK/PD Animal (cat.) | Mouse | Mouse | In vitro |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | PD |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat | Mouse |
Toxicology Animal (cat.) | Mouse, Rat | NHP | Mouse |
Toxicology Major finding | — | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | — |
Toxicology CRS | — | N/A | — |
Clinical Primary efficacy | HbA1c ↓2.4% | Weight ↓14.9% | ORR 0.45% |
Clinical ORR | HbA1c ↓2.4% (SURPASS-2 vs semaglutide 1 mg) | Weight ↓14.9% vs placebo (STEP 1) | -0.45 |
Clinical PFS | Weight ↓20% at 72 wk (SURMOUNT-1) | MACE benefit in SELECT (obesity + CVD) | — |
Clinical Result source | SURPASS-2 / SURMOUNT-1 | STEP 1 / SELECT | ClinicalTrials.gov NCT02912468 |
Clinical Data Tier / Score | S · 77 | B · 75 | C · 65 |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Dose / schedule | — | q1w SC (titrated) or oral daily | — |
Clinical Clinical sync | 2026년 7월 20일 (7일 전) | 2026년 7월 20일 (7일 전) | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교